Results 191 to 200 of about 2,127,832 (378)

Protein‐Like Polymers Targeting Keap1/Nrf2 as Therapeutics for Myocardial Infarction

open access: yesAdvanced Materials, EarlyView.
We describe a Keap1 targeting protein‐like polymer (PLP) which activates Nrf2, an important cytoprotective transcription factor for relieving myocardial infarction‐induced oxidative stress. This PLP increases cell survival in vitro in multiple relevant cardiac cell types and elicits pro‐reparative responses, improving cardiac function in a preclinical ...
Joshua M. Mesfin   +17 more
wiley   +1 more source

Mitochondrial Transplantation via Magnetically Responsive Artificial Cells Promotes Intracerebral Hemorrhage Recovery by Supporting Microglia Immunological Homeostasis

open access: yesAdvanced Materials, Volume 37, Issue 13, April 2, 2025.
A type of magnetically responsive artificial cells (ACs) has been developed, demonstrating the loading of mitochondria and self‐enclosure processes to ensure the protection of mitochondrial transport via the bloodstream. The treatment with ACs effectively transplanted mitochondria around the lesion, thereby improving neurological recovery by supporting
Mi Zhou   +10 more
wiley   +1 more source

Injection site reactions of biologics and mitigation strategies

open access: yesAAPS Open
Biological products administered via subcutaneous (SC) injections offer an effective and convenient alternative to those administered via traditional intravenous injections and have gained a significant increase among approved drugs in recent years ...
Li Zhi, Dingjiang Liu, Mohammed Shameem
doaj   +1 more source

Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. [PDF]

open access: yesCell Death Dis, 2018
Hu C   +11 more
europepmc   +1 more source

Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy

open access: yesAdvanced Materials, EarlyView.
This study develops a multifunctional CRISPR‐dCas9‐based OMV platform termed OMV‐C9I12, which facilitates the coexpression of CXCL9 and IL‐12 within tumor cells. This platform enhances T cell recruitment and activation, synergizes with anti‐PD‐1/PD‐L1 immunotherapy, and amplifies antitumor T cell immunity.
Hongjin Wang   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy